UiPath Advances Open Agentic Ecosystem through
NEW YORK--(BUSINESS WIRE)--UiPath (NYSE: PATH), a global leader in agentic automation, today announced new capabilities that enable the orchestration of Microsoft Copilot Studio agents alongside UiPath and other third-party agents using UiPath Maestro™, an enterprise orchestration solution to seamlessly coordinate agents, robots, and people across complex processes. Developers can now orchestrate Microsoft Copilot Studio agents directly from Maestro.
This capability builds on bi-directional integration between the UiPath Platform™ and Microsoft Copilot Studio recently announced by Microsoft, that facilitates seamless interaction between UiPath and Microsoft agents and automations — allowing customers to automate complex end-to-end processes, enable contextual decision-making, improve scalability, and unlock new levels of productivity. Developers can now embed UiPath automations and AI agents directly into Microsoft Copilot Studio and integrate Copilot agents within UiPath Studio— all while orchestrating seamlessly across platforms with UiPath Maestro.
'Our continued partnership with Microsoft enables millions of Microsoft users to take full advantage of the capabilities and flexibility offered by agentic automation and orchestration,' said Graham Sheldon, Chief Product Officer at UiPath. 'The UiPath multi-agent, cross-system capability uniquely enables seamless interaction and collaboration across various enterprise systems and applications, breaking down silos and enhancing overall operational efficiency.'
Building an Open Ecosystem
Business processes are complex, spanning modern SaaS systems, legacy platforms, documents, desktop applications and user actions.
As several agentic platforms continue to take 'walled garden' approaches, UiPath is committed to building an open ecosystem so customers can focus on business outcomes without getting bogged down by technology limitations. UiPath Maestro can leverage the bi-directional integration with Copilot Studio to give customers built-in capabilities to build, manage, and orchestrate agents built in Microsoft Copilot Studio and other platforms in a controlled and scalable way—all while driving tangible business outcomes.
'You cannot automate a process in isolation; integrating across technology boundaries is necessary for real business impact,' remarked Ramnath Natarajan, Director of Global Intelligent Automation & Integration at Johnson Controls.
Real World Applications
Customers who use Microsoft Copilot Studio agents and Power Automate for email monitoring, email classification and intelligent Q&A are already seeing measurable ROI by augmenting their processes with UiPath agentic automation.
For example, Johnson Controls enhanced an existing automation—originally built with UiPath robots and Power Automate—by adding a UiPath agent for confidence-based document extraction. The result: a 500% return on investment and projected savings of 18,000 hours annually that were previously spent on manual document review.
'This bi-directional integration harnesses the combined strengths of Microsoft Copilot and UiPath agents to fully automate complex workflows across documents, emails, PowerApps, and enterprise systems,' added Ramnath Natarajan, Director of Global Intelligent Automation & Integration Johnson Controls.
Empowering Developers
The integration extends other new capabilities that elevate business processes and drive smarter outcomes with agentic automation across departments and platforms. For instance, customers can now run coded agents built using LangGraph natively on the UiPath Platform without changing a single line of code. This empowers professional developers to build and test their agents using Python tooling while getting advantages of the UiPath Platform including governance, security, evaluations, and more—while running LangChain agents in their business process.
Developers can also use UiPath UI Agent for computer use, to navigate real-world enterprise interfaces. The UiPath UI Agent understands intent, plans, and acts autonomously using a combination of computer use models and UiPath industry leading UI Automation. UI Agent is currently in private preview.
Partnership with Microsoft
UiPath has partnered with Microsoft to build a joint agentic vision anchored on industry leadership and customer choice. These integrations join the availability of its enhanced Autopilot agent for Copilot for Microsoft 365 and Microsoft Teams, allowing joint customers access to UiPath enterprise-grade automation capabilities from anywhere they use Copilot for Microsoft 365 or Teams.
UiPath and Microsoft are also working together to make Azure tools discoverable to UiPath agents with an MCP integration as well as bring models and capabilities built on AI foundry to customers through the UiPath Platform.
To learn more about UiPath agentic automation and our collaboration with Microsoft, visit here or visit the UiPath booth 612 at Microsoft Build 2025 in Seattle or the UiPath virtual booth.
To integrate with UiPath Platform, become a Technology Partner.
About UiPath
UiPath (NYSE: PATH) is a global leader in agentic automation, empowering enterprises to harness the full potential of AI agents to autonomously execute and optimize complex business processes. The UiPath Platform™ uniquely combines controlled agency, developer flexibility, and seamless integration to help organizations scale agentic automation safely and confidently. Committed to security, governance, and interoperability, UiPath supports enterprises as they transition into a future where automation delivers on the full potential of AI to transform industries.
For more information, visit www.uipath.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
37 minutes ago
- Forbes
Microsoft's Bad News—500 Million Windows Users Must Now Decide
Surprising bad news suddenly hits Microsoft. A new warning has been issued for Windows users, whose PCs have been described as 'magnets for security threats,' just as new data gives Microsoft a surprising bad news story ahead of the critical next few months. You can expect many more such warnings as 500-million Windows users face an increasingly urgent decision. The latest advice comes courtesy of PC maker Asus, pointing out that 'if you're still using Windows 10 or, dare we say it, something even older — your computer's days of regular updates and support are numbered.' As for upgrades, 'what makes Windows 11 different?," Asus says. "one word: Copilot," as it pushes the latest range of AI PCs. Clearly, you don't need to decide on a premium Copilot PC to benefit from Windows 11's future-proofing, ensuring your PC receives critical security updates after Windows 10's demise in October. AI PCs remain a niche, despite projections they will eventually dominate new PC sales. Right now, there's a more fundamental decision to make. Windows 10 versus Windows 11 globally. The latest Windows market data presents a painfully bleak picture with just over five months to run until free Windows 10 security updates end for all users. Paid extensions are available, but they're expensive for enterprises and restricted to just 12-months for home users who also must pay. Microsoft is pushing free upgrades not paid extensions. A month ago, it seemed Windows 11 had turned the tide against Windows 10. The newer OS already outanks its older sibling in the U.S. but not globally. Come the end of April, though, Windows 11 was within 10% of Windows 11 for the first time. 'Just over half (53%) of all users are still on Windows 10, but that's inching down month by month.' Not any more, it seems. While more directional than exact, Statcounter's data at the end of May shows a slight month-over-month increase for Windows 10, while Windows 11 dips. This after four months of steady progress the other way. Windows 10 is holding stubbornly above 50% while Windows 11 remains 10% behind. Windows 10 versus Windows 11 in U.S. This means there are around 750 million users are yet to upgrade to Windows 11, of which at least 240 million don't have an eligible PC. That still leaves around 500 million users who can take up Microsoft's offer for a free Windows 11 upgrade but have not. Even in the U.S., where Windows 11 has overtaken Windows 10, May's data suggests Windows 10 has grown its share from 41% in April to more than 43%, while Windows 11 drops a more worrying 3.5%, from 56.5% down to below 53%. All this makes June's data critical. Come the end of this month, there will be just three months until Windows 10 is shuttered. If Microsoft is to avoid a cybersecurity nightmare hitting mid-October, something need to change. For all those Windows 10 users with PCs eligible for a free upgrade, do not run out of time.
Business Upturn
an hour ago
- Business Upturn
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Wire
an hour ago
- Business Wire
Lazard Opens New UK Headquarters in Historic Manchester Square, W1
LONDON--(BUSINESS WIRE)--Lazard, Inc. (NYSE: LAZ) announced today that its new UK headquarters opened at 20 Manchester Square, housing both the firm's Financial Advisory and Asset Management businesses. The new, larger office reflects Lazard's commitment to London as one of the world's leading financial centres and the firm's continued growth in Europe. 20 Manchester Square will become part of Lazard's European footprint and one of its three main global offices, alongside New York and Paris. As a cornerstone of Lazard's international network, the new UK HQ extends the firm's long-standing presence in London which dates back to 1877. Cyrus Kapadia, Co-Head of European Investment Banking and CEO of UK Financial Advisory, said: "The move to 20 Manchester Square underscores our unwavering commitment to the UK and our deep-rooted heritage in London. We have been successfully growing our European teams and network to further support our clients across Europe and around the globe." Jeremy Taylor, CEO of Lazard UK Asset Management said, '20 Manchester Square is more than just a new office—it's a reflection of our values and vision. We are committed to delivering exceptional performance for our clients. This new UK headquarters embodies our dedication to innovation, collaboration, and thoughtful stewardship as we continue to best serve the needs of our clients.' The new building offers modern office space and has been designed with an emphasis on innovation and sustainable standards of construction, technology and use. The space has renewable energy from solar panels on the roof and a rainwater harvesting system. The building's construction adhered to the UK Green Building Council framework for net-zero carbon emissions and recycled, long-life materials with reduced replaceability have been used across floors, walls and ceiling finishes, with water efficient taps, showers and fixtures in place throughout. 20 Manchester Square is situated next door to the Wallace Collection and Regent's Park, and the area is well known for its cultural landmarks and accessible transport links. Lazard UK is relocating from 50 Stratton Street, after over twenty years. ABOUT LAZARD Founded in 1848, Lazard is the preeminent financial advisory and asset management firm, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. For more information, please visit and follow Lazard on LinkedIn.
